H And T Presspart
H And T Presspart, a leading name in the pharmaceutical and healthcare industry, is headquartered in Germany (DE) and operates extensively across Europe and beyond. Founded in the early 1970s, the company has established itself as a pioneer in the development and manufacturing of inhalation devices and drug delivery systems. With a strong focus on innovation, H And T Presspart offers a range of core products, including metered dose inhalers and dry powder inhalers, distinguished by their precision and reliability. The company’s commitment to quality and regulatory compliance has positioned it as a trusted partner for major pharmaceutical firms. Notable achievements include significant advancements in device technology and a robust portfolio that caters to the evolving needs of the healthcare market, solidifying H And T Presspart's reputation as a key player in the global drug delivery landscape.
DitchCarbon Score
How does H And T Presspart's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
H And T Presspart's score of 5 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
H And T Presspart's reported carbon emissions
In 2019, H And T Presspart reported total carbon emissions of approximately 743,606,000 kg CO2e, with emissions distributed across various scopes: 48,936,000 kg CO2e (Scope 1), 15,572,000 kg CO2e (Scope 2, market-based), and 743,606,000 kg CO2e (Scope 3). In 2020, the company further reduced its emissions to about 769,239,000 kg CO2e, with Scope 1 emissions at 43,846,000 kg CO2e and Scope 2 emissions at 2,030,000 kg CO2e (market-based). H And T Presspart has committed to achieving net-zero emissions by 2050, as part of its long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which the company joined in December 2022. The SBTi framework encourages companies to set science-based emissions reduction targets, ensuring that their strategies contribute to global climate goals. The company has demonstrated a proactive approach to reducing its carbon footprint, particularly in Scope 1 and Scope 2 emissions, while also addressing the significant impact of Scope 3 emissions, which include indirect emissions from the supply chain and product use. H And T Presspart's ongoing efforts reflect its dedication to sustainability and climate responsibility within the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2010 | 2011 | 2012 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Scope 1 | 1,805,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 430,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | 4,647,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
H And T Presspart is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
